Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$45.46 – $100.48
101% from low
Exchange
NASDAQ
ETF
Borrow rate
9.08%
Hard to borrow
No company description on file.
No one on the platform currently holds BIB.
No tracked institution reports a position in BIB as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-03-25 | $0.0071 | 2026-03-31 |
| 2025-12-24 | $0.1346 | 2025-12-31 |
| 2025-09-24 | $0.1805 | 2025-09-30 |
| 2025-06-25 | $0.1706 | 2025-07-01 |
| 2025-03-26 | $0.1309 | 2025-04-01 |
| 2024-12-23 | $0.3964 | 2024-12-31 |
| 2024-09-25 | $0.1528 | 2024-10-02 |
| 2024-06-26 | $0.2648 | 2024-07-03 |
| 2024-03-20 | $0.0403 | 2024-03-27 |
| 2023-12-20 | $0.0384 | 2023-12-28 |
No one on the platform has traded BIB yet.
| +0.23% |
| $82M |
| — |
| ITDCiShares LifePath Target Date 2035 ETF | $36.58 | +0.52% | $100M | — |
| NACPImpact Shares NAACP Minority Empowerment ETF | $60.22 | +1.60% | $76M | — |
Source: Financial Modeling Prep · peers by sector/industry
| Execution date | Ratio |
|---|---|
| 2015-05-20 | 2-for-1 |
| 2014-01-24 | 2-for-1 |
| 2012-10-05 | 2-for-1 |
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$LXRX Aaaand there's this **NEWS JUST OUT**= VERY VERY BIG (In my view) = STARTING TOMORROW JULY 1st = GLP -1 's now covered by Medicare The Medicare GLP-1 Bridge Program is scheduled to last for exactly 18 months, running from July 1, 2026, through December 31, 2027.Because this is launched as a federal demonstration pilot rather than a permanent change to the law, the program will automatically expire at the end of 2027 unless Congress passes new legislation to permanently overturn the decades-old ban on Medicare weight-loss coverage. Because federal law explicitly bans Medicare from covering weight-loss drugs, the current 18-month program is a loophole called a "demonstration project." The executive branch uses these projects to test new coverage rules temporarily, but they cannot keep them going indefinitely without a legislative change. https://www.medicare.gov/coverage/weight-loss-drugs $VRTS $NVO $LLY $BIB
View on StockTwits ↗the case for biotech and the breakout good read $xbi $bib $ibb $xlv https://thierryvonarvy.substack.com/p/the-biotech-breakout
View on StockTwits ↗$BIB $LXRX $NVO $VTRS 🇯🇵 Since 2018, Japan has approved Suglat (ipragliflozin) as an insulin add-on for T1D — first SGLT2i cleared there. A patient satisfaction survey (DTSQ) showed real QoL gains: better glucose control, lower insulin needs. 🇺🇸 Sotagliflozin (Zynquista— same dual SGLT1/2 class — showed comparable benefits in inTandem trials: lower A1C, reduced bodyweight, less insulin required, sustained over 52 weeks. FDA gave feedback that the STENO1 study (Steno Diabetes Center) is adequately designed to provide DKA safety data supporting an NDA resubmission, with potential 2026 approval if requirements are met. STENO1 is past 50% enrollment, completing mid-2026 Breakthrough T1D backed early Zynquista trials citing significant blood-sugar reduction. Dr. Steve Edelman (UCSD/TCOYD) testified insulin alone isn’t enough for many T1D patients. =fewer/smaller insulin shots, tighter glucose control, better daily QoL — echoing what Japan’s T1D patients have reported since 2018.
View on StockTwits ↗$BIB $LXRX $NVO $VTRS This cerebras expert is now a Lexicon Pharma Expert. Cute.
View on StockTwits ↗$BIB $LXRX $NVO $VTRS YOU FOOL. EVERYBODY KNOWS YOU STILL NEED INSULIN. ONLY AN IDIOT WOULD BELIEVE OTHERWISE. A POST THAT EMPHASIZES THE BENEFITS OF A PILL OVER PUMPING INSULIN ARE IRREFUTABLE LIKE THAT HAVE BEEN IN JAPAN SINCE 2019.
View on StockTwits ↗$LXRX = FDA DECISION COMING SHORTLY!! NO MORE PAINFUL INSULIN SHOTS FOR TYPE 1 Diabetes!!! FIRST ORAL PILL EVER!!!!! 💪😉🇺🇸🙏 $BIB partners = $NVO and $VTRS
View on StockTwits ↗$LXRX 💪😉 $BIB $UNH our partners = $NVO $VTRS
View on StockTwits ↗$LXRX Type 1 DIABETES = ABOUT TO GET PAWNED. $BIB $UNH Our partners = $NVO $VTRS
View on StockTwits ↗$LABU $LABD $XBI $IBB $BIB Go bulls. Buyout boost vs CPI.
View on StockTwits ↗$LABU $LABD $XBI $IBB $BIB 3 bio buyouts. Incyte/Vega 2B. J&J/Firefly Bio 1B.. GSK/Nuvalent 10.6B That is 13.6B in buyouts. XBI 138. Here we come again. https://www.bioworld.com/articles/731689-incyte-nabs-potential-vwd-game-changer-in-vega-deal-j-and-j-buys-firefly https://www.fiercebiotech.com/biotech/gsk-inks-10.6b-nuvalent-buyout-challenge-roche-and-pfizer-lung-cancer
View on StockTwits ↗$RVMD $XBI $LABU $BIB $SPY Revolutions $RVMD Daraxorasib alone or in combination with others in pancreatic cancer improved survival rates drastically. Tango plans to test the vopimetostat-daraxonrasib combination in first-line pancreatic cancer patients with a genetic mutation known as MTAP deletion, pending discussions with regulators. On going studies showing similar results in Lung and Rectal cancers.
View on StockTwits ↗$CMPS The Michigan House Families and Veterans Committee held a hearing on a bill to create an ibogaine grant program to support research on whether the psychedelic is effective in treating substance use disorder and other mental health conditions—using $50 million in opioid settlement funds. https://x.com/tomangell/status/2063242961844883492?s=46 $BIB
View on StockTwits ↗$RVMD $SPY $BIB $LABU $XBI https://www.streetwisereports.com/article/2026/06/04/california-pharma-co-tests-breakthrough-cancer-drug-cuts-death-risk-60.html
View on StockTwits ↗$LXRX 🚨 NEVER-BEFORE-SEEN DATA drops Sunday June 7 at ADA 2026. Pilavapadin Phase 1 renal PK study — first public presentation ever. Here's why this is HUGE: → DPNP patients almost universally have damaged kidneys (diabetes destroys them) → Every current pain drug — pregabalin, duloxetine, gabapentin — requires dose adjustments in kidney disease, creating prescribing nightmares → Pilavapadin? Renal function does NOT affect how this drug behaves in the body → No dose adjustment. No renal testing. Prescribe to virtually the entire DPNP population cleanly This removes the #1 real-world barrier to a new DPNP drug getting prescribed broadly. Clean FDA label. Massive commercial upside. Active partnership talks ongoing. Non-opioid. CNS-penetrant. Novel AAK1 mechanism. Presented by Dr. Rodica Pop-Busui — OHSU — independent world-class DPNP researcher. Not a Lexicon employee. NDA resubmission for sotagliflozin T1D also imminent — mid-2026. Two pipeline drugs. ~$245M market cap $BIB $VTRS $NVO
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.